Further research is needed to understand why certain individuals carrying p16-L16R or other germline CDKN2A mutations develop melanoma, pancreatic cancer, or other malignancies and why penetrance of these mutations is less than 100% (2, 36, 37, 38). This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.